Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-grade glioma tumor concentrations of protein kinase inhibitors
NL-OMON28204Not yet recruiting
- Sponsor
- VU University Medical Center De Boelelaan 117, 1081 HV Amsterdam
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sunitinib, vandetanib and erlotinib in glioma (4 arms), sponsored by VU University Medical Center De Boelelaan 117, 1081 HV Amsterdam. Primary endpoint: Tumor concentration of protein kinase inhibitors and active metabolites. Planned start Sep 2014; status: not yet recruiting.
02
Drugs
sunitinibvandetaniberlotinib
03
Conditions
glioma
Beyond the preview
Go deeper on NL-OMON28204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28204.